A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE) View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey, Ignacio Duran, Luc Dirix, Karen Geboes, Christine Wilkinson-Blanc, Gillian Pover, Simon Alvis, Brian Champion, Kerry Fisher, Hilary McElwaine-Johnn, John Beadle, Emiliano Calvo

ABSTRACT

BACKGROUND: Enadenotucirev is a chimeric adenovirus with demonstrated preclinical tumor-selective cytotoxicity and a short half-life. Further clinical mechanism of action data showed that enadenotucirev can gain access to and replicate within different types of epithelial tumors. This phase 1 dose escalation study assessed intravenous (IV) dose escalation with enadenotucirev to establish the maximum tolerated dose (MTD) and subsequently identify a suitable schedule for repeated cycles. METHODS: Sixty-one patients with advanced epithelial tumors unresponsive to conventional therapy were enrolled and received enadenotucirev monotherapy as part of this study. During the phase 1a dose escalation (n = 22) and expansion (n = 9), delivery of enadenotucirev between 1 × 1010 and 1 × 1013 viral particles (vp) on days 1, 3, and 5 (single cycle) was used to determine an appropriate MTD. Subsequent treatment cohorts (phase 1a, n = 6 and phase 1b, n = 24) examined the feasibility of repeated dosing cycles in either 3-weekly or weekly dosing regimens. RESULTS: Enadenotucirev displayed a predictable and manageable safety profile at doses up to the MTD of 3 × 1012 vp, irrespective of infusion time or dosing schedule. The most commonly reported treatment-emergent adverse events (TEAEs) of grade 3 or higher were hypoxia, lymphopenia, and neutropenia. The frequency of all TEAEs (notably pyrexia and chills) was highest within 24 h of the first enadenotucirev infusion and decreased upon subsequent dosing. Additionally, delivery of three doses of enadenotucirev over 5 days optimized pharmacokinetic and chemokine profiles in the circulation over time. CONCLUSIONS: This study provides key clinical data in patients with solid epithelial tumors following treatment with IV enadenotucirev monotherapy and supports further investigation of enadenotucirev in combination with other therapeutic agents at doses up to the MTD of 3 × 1012 vp. TRIAL REGISTRATION: ( ClinicalTrials.gov Identifier: NCT02028442 ). Trial registration date: 07 January 2014 - Retrospectively registered. More... »

PAGES

20

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40425-019-0510-7

DOI

http://dx.doi.org/10.1186/s40425-019-0510-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1111750987

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30691536


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Universit\u00e9 Catholique de Louvain", 
          "id": "https://www.grid.ac/institutes/grid.7942.8", 
          "name": [
            "Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Exp\u00e9rimentale, Universit\u00e9 catholique de Louvain, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Machiels", 
        "givenName": "Jean-Pascal", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Barcelona", 
          "id": "https://www.grid.ac/institutes/grid.5841.8", 
          "name": [
            "Medical Oncology Department, Catalan Institute of Oncology, IDIBELL, University of Barcelona, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Salazar", 
        "givenName": "Ramon", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ghent University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.410566.0", 
          "name": [
            "Drug Research Unit Ghent, Ghent University Hospital, Ghent, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rottey", 
        "givenName": "Sylvie", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Biomedicine of Seville", 
          "id": "https://www.grid.ac/institutes/grid.414816.e", 
          "name": [
            "Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Roc\u00edo/CSIC/Universidad de Sevilla, Seville, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Duran", 
        "givenName": "Ignacio", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Saint-Augustinus Hospital, Antwerp, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dirix", 
        "givenName": "Luc", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ghent University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.410566.0", 
          "name": [
            "Department of Gastroenterology and Digestive Oncology, Ghent University Hospital, Ghent, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Geboes", 
        "givenName": "Karen", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PsiOxus Therapeutics (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.476643.4", 
          "name": [
            "PsiOxus Therapeutics Limited, 4\u201310 The Quadrant, Barton Lane, Abingdon, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wilkinson-Blanc", 
        "givenName": "Christine", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PsiOxus Therapeutics (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.476643.4", 
          "name": [
            "PsiOxus Therapeutics Limited, 4\u201310 The Quadrant, Barton Lane, Abingdon, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pover", 
        "givenName": "Gillian", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PsiOxus Therapeutics (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.476643.4", 
          "name": [
            "PsiOxus Therapeutics Limited, 4\u201310 The Quadrant, Barton Lane, Abingdon, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Alvis", 
        "givenName": "Simon", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PsiOxus Therapeutics (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.476643.4", 
          "name": [
            "PsiOxus Therapeutics Limited, 4\u201310 The Quadrant, Barton Lane, Abingdon, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Champion", 
        "givenName": "Brian", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "PsiOxus Therapeutics Limited, 4\u201310 The Quadrant, Barton Lane, Abingdon, UK", 
            "Department of Oncology, University of Oxford, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fisher", 
        "givenName": "Kerry", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PsiOxus Therapeutics (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.476643.4", 
          "name": [
            "PsiOxus Therapeutics Limited, 4\u201310 The Quadrant, Barton Lane, Abingdon, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McElwaine-Johnn", 
        "givenName": "Hilary", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PsiOxus Therapeutics (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.476643.4", 
          "name": [
            "PsiOxus Therapeutics Limited, 4\u201310 The Quadrant, Barton Lane, Abingdon, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Beadle", 
        "givenName": "John", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "HM Hospitales", 
          "id": "https://www.grid.ac/institutes/grid.428486.4", 
          "name": [
            "START Madrid, Centro Integral Oncol\u00f3gico Clara Campal, Hospital Madrid Norte Sanchinarro, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Calvo", 
        "givenName": "Emiliano", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1155/2012/805629", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011454600"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/gt.2014.2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011736221", 
          "https://doi.org/10.1038/gt.2014.2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/gt.2014.2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011736221", 
          "https://doi.org/10.1038/gt.2014.2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2015.481", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012232860", 
          "https://doi.org/10.1038/bjc.2015.481"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/scitranslmed.3003689", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018365419"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaoncol.2016.2064", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020101780"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.omto.2016.11.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033108428"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nbt.2287", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034396211", 
          "https://doi.org/10.1038/nbt.2287"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1038/mt.2015.233", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038729193"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2010.335", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040147725", 
          "https://doi.org/10.1038/onc.2010.335"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2010.335", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040147725", 
          "https://doi.org/10.1038/onc.2010.335"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00262-004-0593-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042196140", 
          "https://doi.org/10.1007/s00262-004-0593-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/jvi.78.23.13207-13215.2004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042913034"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.67.1529", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043635894"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0002409", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044534807"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ymthe.2006.02.011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047695078"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc3239", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047946992", 
          "https://doi.org/10.1038/nrc3239"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/jvi.77.15.8263-8271.2003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048816043"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc3770", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053470348", 
          "https://doi.org/10.1038/nrc3770"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ctrv.2017.01.008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083745519"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.omto.2017.03.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084100092"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.ppat.1006190", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084310309"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ymthe.2017.03.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084535871"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0177810", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085595745"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.15252/emmm.201707567", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086093337"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s40425-017-0277-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091472881", 
          "https://doi.org/10.1186/s40425-017-0277-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cell.2017.08.027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091503595"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: Enadenotucirev is a chimeric adenovirus with demonstrated preclinical tumor-selective cytotoxicity and a short half-life. Further clinical mechanism of action data showed that enadenotucirev can gain access to and replicate within different types of epithelial tumors. This phase 1 dose escalation study assessed intravenous (IV) dose escalation with enadenotucirev to establish the maximum tolerated dose (MTD) and subsequently identify a suitable schedule for repeated cycles.\nMETHODS: Sixty-one patients with advanced epithelial tumors unresponsive to conventional therapy were enrolled and received enadenotucirev monotherapy as part of this study. During the phase 1a dose escalation (n\u00a0=\u200922) and expansion (n\u00a0=\u20099), delivery of enadenotucirev between 1\u2009\u00d7\u20091010 and 1\u2009\u00d7\u20091013 viral particles (vp) on days 1, 3, and 5 (single cycle) was used to determine an appropriate MTD. Subsequent treatment cohorts (phase 1a, n\u00a0=\u20096 and phase 1b, n\u00a0=\u200924) examined the feasibility of repeated dosing cycles in either 3-weekly or weekly dosing regimens.\nRESULTS: Enadenotucirev displayed a predictable and manageable safety profile at doses up to the MTD of 3\u2009\u00d7\u20091012 vp, irrespective of infusion time or dosing schedule. The most commonly reported treatment-emergent adverse events (TEAEs) of grade 3 or higher were hypoxia, lymphopenia, and neutropenia. The frequency of all TEAEs (notably pyrexia and chills) was highest within 24\u2009h of the first enadenotucirev infusion and decreased upon subsequent dosing. Additionally, delivery of three doses of enadenotucirev over 5\u2009days optimized pharmacokinetic and chemokine profiles in the circulation over time.\nCONCLUSIONS: This study provides key clinical data in patients with solid epithelial tumors following treatment with IV enadenotucirev monotherapy and supports further investigation of enadenotucirev in combination with other therapeutic agents at doses up to the MTD of 3\u2009\u00d7\u20091012 vp.\nTRIAL REGISTRATION: ( ClinicalTrials.gov Identifier: NCT02028442 ). Trial registration date: 07 January 2014 - Retrospectively registered.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s40425-019-0510-7", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1049249", 
        "issn": [
          "2051-1426"
        ], 
        "name": "Journal for ImmunoTherapy of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "name": "A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)", 
    "pagination": "20", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "46c967fe03c89d9cee09f6a65fe9ac8a10ebfc270fe695b2d6c5560d178b289c"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30691536"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101620585"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40425-019-0510-7"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1111750987"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40425-019-0510-7", 
      "https://app.dimensions.ai/details/publication/pub.1111750987"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T08:59", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000327_0000000327/records_114970_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs40425-019-0510-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0510-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0510-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0510-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0510-7'


 

This table displays all metadata directly associated to this object as RDF triples.

250 TRIPLES      21 PREDICATES      54 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40425-019-0510-7 schema:about anzsrc-for:11
2 anzsrc-for:1115
3 schema:author N1f0bc3acef4142deb836b407ee1e171a
4 schema:citation sg:pub.10.1007/s00262-004-0593-x
5 sg:pub.10.1038/bjc.2015.481
6 sg:pub.10.1038/gt.2014.2
7 sg:pub.10.1038/nbt.2287
8 sg:pub.10.1038/nrc3239
9 sg:pub.10.1038/nrc3770
10 sg:pub.10.1038/onc.2010.335
11 sg:pub.10.1186/s40425-017-0277-7
12 https://doi.org/10.1001/jamaoncol.2016.2064
13 https://doi.org/10.1016/j.cell.2017.08.027
14 https://doi.org/10.1016/j.ctrv.2017.01.008
15 https://doi.org/10.1016/j.omto.2016.11.003
16 https://doi.org/10.1016/j.omto.2017.03.003
17 https://doi.org/10.1016/j.ymthe.2006.02.011
18 https://doi.org/10.1016/j.ymthe.2017.03.026
19 https://doi.org/10.1038/mt.2015.233
20 https://doi.org/10.1126/scitranslmed.3003689
21 https://doi.org/10.1128/jvi.77.15.8263-8271.2003
22 https://doi.org/10.1128/jvi.78.23.13207-13215.2004
23 https://doi.org/10.1155/2012/805629
24 https://doi.org/10.1200/jco.2016.67.1529
25 https://doi.org/10.1371/journal.pone.0002409
26 https://doi.org/10.1371/journal.pone.0177810
27 https://doi.org/10.1371/journal.ppat.1006190
28 https://doi.org/10.15252/emmm.201707567
29 schema:datePublished 2019-12
30 schema:datePublishedReg 2019-12-01
31 schema:description BACKGROUND: Enadenotucirev is a chimeric adenovirus with demonstrated preclinical tumor-selective cytotoxicity and a short half-life. Further clinical mechanism of action data showed that enadenotucirev can gain access to and replicate within different types of epithelial tumors. This phase 1 dose escalation study assessed intravenous (IV) dose escalation with enadenotucirev to establish the maximum tolerated dose (MTD) and subsequently identify a suitable schedule for repeated cycles. METHODS: Sixty-one patients with advanced epithelial tumors unresponsive to conventional therapy were enrolled and received enadenotucirev monotherapy as part of this study. During the phase 1a dose escalation (n = 22) and expansion (n = 9), delivery of enadenotucirev between 1 × 1010 and 1 × 1013 viral particles (vp) on days 1, 3, and 5 (single cycle) was used to determine an appropriate MTD. Subsequent treatment cohorts (phase 1a, n = 6 and phase 1b, n = 24) examined the feasibility of repeated dosing cycles in either 3-weekly or weekly dosing regimens. RESULTS: Enadenotucirev displayed a predictable and manageable safety profile at doses up to the MTD of 3 × 1012 vp, irrespective of infusion time or dosing schedule. The most commonly reported treatment-emergent adverse events (TEAEs) of grade 3 or higher were hypoxia, lymphopenia, and neutropenia. The frequency of all TEAEs (notably pyrexia and chills) was highest within 24 h of the first enadenotucirev infusion and decreased upon subsequent dosing. Additionally, delivery of three doses of enadenotucirev over 5 days optimized pharmacokinetic and chemokine profiles in the circulation over time. CONCLUSIONS: This study provides key clinical data in patients with solid epithelial tumors following treatment with IV enadenotucirev monotherapy and supports further investigation of enadenotucirev in combination with other therapeutic agents at doses up to the MTD of 3 × 1012 vp. TRIAL REGISTRATION: ( ClinicalTrials.gov Identifier: NCT02028442 ). Trial registration date: 07 January 2014 - Retrospectively registered.
32 schema:genre research_article
33 schema:inLanguage en
34 schema:isAccessibleForFree true
35 schema:isPartOf N9f1d6e9703644767920ad12459810631
36 Naf9f371fae92439ab86db116eef675b8
37 sg:journal.1049249
38 schema:name A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
39 schema:pagination 20
40 schema:productId N20f12f162d0543e58f6c0015eeeae5d8
41 N23f1d5cc080245cbad2c01bc2131dac0
42 N2f61e2f7ef324010956eb9c1f8949b44
43 N40525dce98734ba3b0c67ea734fe112b
44 N7a2db41b0f464bdea1fba75437fda5d6
45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111750987
46 https://doi.org/10.1186/s40425-019-0510-7
47 schema:sdDatePublished 2019-04-11T08:59
48 schema:sdLicense https://scigraph.springernature.com/explorer/license/
49 schema:sdPublisher Ncb6c7b19ac854dc7b2de9db4c2bd7120
50 schema:url https://link.springer.com/10.1186%2Fs40425-019-0510-7
51 sgo:license sg:explorer/license/
52 sgo:sdDataset articles
53 rdf:type schema:ScholarlyArticle
54 N0a2aad35054d4418952734b470d84c42 rdf:first Nb9012ca2f8244a328139a598f8af1099
55 rdf:rest N76c6413d9b7c4bbab5601dee8bb69fa2
56 N0f58189191df4e298b6ea7cf2495cbec schema:affiliation https://www.grid.ac/institutes/grid.4991.5
57 schema:familyName Fisher
58 schema:givenName Kerry
59 rdf:type schema:Person
60 N12335a323c11412093cc50286f6b9928 rdf:first N7cddf7ffe804443cbea9b7d19ae06072
61 rdf:rest Naf013b2b6bcc43bc87e41849cbb2fd0d
62 N15f4b970492d40dca164cea5325d2574 schema:affiliation https://www.grid.ac/institutes/grid.476643.4
63 schema:familyName Beadle
64 schema:givenName John
65 rdf:type schema:Person
66 N18079bf9bebd4c3bb23fc4b9eb91e8b5 schema:name Saint-Augustinus Hospital, Antwerp, Belgium
67 rdf:type schema:Organization
68 N1f0bc3acef4142deb836b407ee1e171a rdf:first N6ceeea9a5bbe4aa487e5c805e3404329
69 rdf:rest Nfd2c66f364d24d3a915390c72b9fdbfe
70 N20f12f162d0543e58f6c0015eeeae5d8 schema:name readcube_id
71 schema:value 46c967fe03c89d9cee09f6a65fe9ac8a10ebfc270fe695b2d6c5560d178b289c
72 rdf:type schema:PropertyValue
73 N23f1d5cc080245cbad2c01bc2131dac0 schema:name dimensions_id
74 schema:value pub.1111750987
75 rdf:type schema:PropertyValue
76 N2f61e2f7ef324010956eb9c1f8949b44 schema:name doi
77 schema:value 10.1186/s40425-019-0510-7
78 rdf:type schema:PropertyValue
79 N33f2e9fe4f904adbbb2606272284c4d7 schema:affiliation N18079bf9bebd4c3bb23fc4b9eb91e8b5
80 schema:familyName Dirix
81 schema:givenName Luc
82 rdf:type schema:Person
83 N3c8d18e190084fbe8c0f8b4f51e9041a rdf:first N15f4b970492d40dca164cea5325d2574
84 rdf:rest N505a446beb3846c6a46352e3d49694d1
85 N40525dce98734ba3b0c67ea734fe112b schema:name nlm_unique_id
86 schema:value 101620585
87 rdf:type schema:PropertyValue
88 N48ef235417304380af674d4518aee952 schema:affiliation https://www.grid.ac/institutes/grid.428486.4
89 schema:familyName Calvo
90 schema:givenName Emiliano
91 rdf:type schema:Person
92 N4ebdba81d26145daa5b141808ddbc237 schema:affiliation https://www.grid.ac/institutes/grid.476643.4
93 schema:familyName Champion
94 schema:givenName Brian
95 rdf:type schema:Person
96 N505a446beb3846c6a46352e3d49694d1 rdf:first N48ef235417304380af674d4518aee952
97 rdf:rest rdf:nil
98 N573d2de08df94c52a168597c501d0fe6 schema:affiliation https://www.grid.ac/institutes/grid.476643.4
99 schema:familyName Wilkinson-Blanc
100 schema:givenName Christine
101 rdf:type schema:Person
102 N6ceeea9a5bbe4aa487e5c805e3404329 schema:affiliation https://www.grid.ac/institutes/grid.7942.8
103 schema:familyName Machiels
104 schema:givenName Jean-Pascal
105 rdf:type schema:Person
106 N76c6413d9b7c4bbab5601dee8bb69fa2 rdf:first N573d2de08df94c52a168597c501d0fe6
107 rdf:rest N12335a323c11412093cc50286f6b9928
108 N7a2db41b0f464bdea1fba75437fda5d6 schema:name pubmed_id
109 schema:value 30691536
110 rdf:type schema:PropertyValue
111 N7cddf7ffe804443cbea9b7d19ae06072 schema:affiliation https://www.grid.ac/institutes/grid.476643.4
112 schema:familyName Pover
113 schema:givenName Gillian
114 rdf:type schema:Person
115 N85ce2231ee734914aba25b38066d8fbe schema:affiliation https://www.grid.ac/institutes/grid.410566.0
116 schema:familyName Rottey
117 schema:givenName Sylvie
118 rdf:type schema:Person
119 N8f6659fb01744a53ba8230e94e7e612c schema:affiliation https://www.grid.ac/institutes/grid.476643.4
120 schema:familyName Alvis
121 schema:givenName Simon
122 rdf:type schema:Person
123 N8f9da17f11e64aa0963dae257ec99e6d rdf:first N0f58189191df4e298b6ea7cf2495cbec
124 rdf:rest Nf24fd636b8ed422cb4d1e79187520220
125 N9f1d6e9703644767920ad12459810631 schema:volumeNumber 7
126 rdf:type schema:PublicationVolume
127 Na893834e23e34a1eba1ce3343360cc8c schema:affiliation https://www.grid.ac/institutes/grid.5841.8
128 schema:familyName Salazar
129 schema:givenName Ramon
130 rdf:type schema:Person
131 Naf013b2b6bcc43bc87e41849cbb2fd0d rdf:first N8f6659fb01744a53ba8230e94e7e612c
132 rdf:rest Nf970ce3f3e3743f6a59ed45315a5061f
133 Naf9f371fae92439ab86db116eef675b8 schema:issueNumber 1
134 rdf:type schema:PublicationIssue
135 Naffe30a049e04e02ac9fab5e24264caa schema:affiliation https://www.grid.ac/institutes/grid.476643.4
136 schema:familyName McElwaine-Johnn
137 schema:givenName Hilary
138 rdf:type schema:Person
139 Nb9012ca2f8244a328139a598f8af1099 schema:affiliation https://www.grid.ac/institutes/grid.410566.0
140 schema:familyName Geboes
141 schema:givenName Karen
142 rdf:type schema:Person
143 Nc261f74ca11b4f07a201890820ee2e4e rdf:first N85ce2231ee734914aba25b38066d8fbe
144 rdf:rest Nc8ece07bf6b24643a78f210ab9edd42b
145 Nc8ece07bf6b24643a78f210ab9edd42b rdf:first Ne4cd7d9bf5ac4fc081ee0457cdc6e83d
146 rdf:rest Nf38b0da9695d4a7498dfd203b70c0f0e
147 Ncb6c7b19ac854dc7b2de9db4c2bd7120 schema:name Springer Nature - SN SciGraph project
148 rdf:type schema:Organization
149 Ne4cd7d9bf5ac4fc081ee0457cdc6e83d schema:affiliation https://www.grid.ac/institutes/grid.414816.e
150 schema:familyName Duran
151 schema:givenName Ignacio
152 rdf:type schema:Person
153 Nf24fd636b8ed422cb4d1e79187520220 rdf:first Naffe30a049e04e02ac9fab5e24264caa
154 rdf:rest N3c8d18e190084fbe8c0f8b4f51e9041a
155 Nf38b0da9695d4a7498dfd203b70c0f0e rdf:first N33f2e9fe4f904adbbb2606272284c4d7
156 rdf:rest N0a2aad35054d4418952734b470d84c42
157 Nf970ce3f3e3743f6a59ed45315a5061f rdf:first N4ebdba81d26145daa5b141808ddbc237
158 rdf:rest N8f9da17f11e64aa0963dae257ec99e6d
159 Nfd2c66f364d24d3a915390c72b9fdbfe rdf:first Na893834e23e34a1eba1ce3343360cc8c
160 rdf:rest Nc261f74ca11b4f07a201890820ee2e4e
161 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
162 schema:name Medical and Health Sciences
163 rdf:type schema:DefinedTerm
164 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
165 schema:name Pharmacology and Pharmaceutical Sciences
166 rdf:type schema:DefinedTerm
167 sg:journal.1049249 schema:issn 2051-1426
168 schema:name Journal for ImmunoTherapy of Cancer
169 rdf:type schema:Periodical
170 sg:pub.10.1007/s00262-004-0593-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1042196140
171 https://doi.org/10.1007/s00262-004-0593-x
172 rdf:type schema:CreativeWork
173 sg:pub.10.1038/bjc.2015.481 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012232860
174 https://doi.org/10.1038/bjc.2015.481
175 rdf:type schema:CreativeWork
176 sg:pub.10.1038/gt.2014.2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011736221
177 https://doi.org/10.1038/gt.2014.2
178 rdf:type schema:CreativeWork
179 sg:pub.10.1038/nbt.2287 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034396211
180 https://doi.org/10.1038/nbt.2287
181 rdf:type schema:CreativeWork
182 sg:pub.10.1038/nrc3239 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047946992
183 https://doi.org/10.1038/nrc3239
184 rdf:type schema:CreativeWork
185 sg:pub.10.1038/nrc3770 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053470348
186 https://doi.org/10.1038/nrc3770
187 rdf:type schema:CreativeWork
188 sg:pub.10.1038/onc.2010.335 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040147725
189 https://doi.org/10.1038/onc.2010.335
190 rdf:type schema:CreativeWork
191 sg:pub.10.1186/s40425-017-0277-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091472881
192 https://doi.org/10.1186/s40425-017-0277-7
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1001/jamaoncol.2016.2064 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020101780
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1016/j.cell.2017.08.027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091503595
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1016/j.ctrv.2017.01.008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083745519
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1016/j.omto.2016.11.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033108428
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1016/j.omto.2017.03.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084100092
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1016/j.ymthe.2006.02.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047695078
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1016/j.ymthe.2017.03.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084535871
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1038/mt.2015.233 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038729193
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1126/scitranslmed.3003689 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018365419
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1128/jvi.77.15.8263-8271.2003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048816043
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1128/jvi.78.23.13207-13215.2004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042913034
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1155/2012/805629 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011454600
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1200/jco.2016.67.1529 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043635894
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1371/journal.pone.0002409 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044534807
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1371/journal.pone.0177810 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085595745
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1371/journal.ppat.1006190 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084310309
225 rdf:type schema:CreativeWork
226 https://doi.org/10.15252/emmm.201707567 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086093337
227 rdf:type schema:CreativeWork
228 https://www.grid.ac/institutes/grid.410566.0 schema:alternateName Ghent University Hospital
229 schema:name Department of Gastroenterology and Digestive Oncology, Ghent University Hospital, Ghent, Belgium
230 Drug Research Unit Ghent, Ghent University Hospital, Ghent, Belgium
231 rdf:type schema:Organization
232 https://www.grid.ac/institutes/grid.414816.e schema:alternateName Institute of Biomedicine of Seville
233 schema:name Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain
234 rdf:type schema:Organization
235 https://www.grid.ac/institutes/grid.428486.4 schema:alternateName HM Hospitales
236 schema:name START Madrid, Centro Integral Oncológico Clara Campal, Hospital Madrid Norte Sanchinarro, Madrid, Spain
237 rdf:type schema:Organization
238 https://www.grid.ac/institutes/grid.476643.4 schema:alternateName PsiOxus Therapeutics (United Kingdom)
239 schema:name PsiOxus Therapeutics Limited, 4–10 The Quadrant, Barton Lane, Abingdon, UK
240 rdf:type schema:Organization
241 https://www.grid.ac/institutes/grid.4991.5 schema:alternateName University of Oxford
242 schema:name Department of Oncology, University of Oxford, Oxford, UK
243 PsiOxus Therapeutics Limited, 4–10 The Quadrant, Barton Lane, Abingdon, UK
244 rdf:type schema:Organization
245 https://www.grid.ac/institutes/grid.5841.8 schema:alternateName University of Barcelona
246 schema:name Medical Oncology Department, Catalan Institute of Oncology, IDIBELL, University of Barcelona, Barcelona, Spain
247 rdf:type schema:Organization
248 https://www.grid.ac/institutes/grid.7942.8 schema:alternateName Université Catholique de Louvain
249 schema:name Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Université catholique de Louvain, Brussels, Belgium
250 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...